S
SwanBio Therapeutics
Gene therapy company focused on the development and commercialisation of genetically defined therapies
About SwanBio Therapeutics
SwanBio Therapeutics is a pioneering gene therapy company dedicated to developing life-changing treatments for individuals suffering from genetically defined neurological disorders. Operating within the biopharmaceutical sector, SwanBio Therapeutics leverages advanced genetic medicines to deliver therapeutic genes directly to the central nervous system (CNS) using adeno-associated viruses (AAVs). This approach is designed to be well-tolerated and effective, aiming to halt the progression of debilitating diseases and enable patients to lead better lives.
Read full description
The company primarily serves patients with severe neurological conditions, offering hope and potential cures where traditional treatments have failed. SwanBio Therapeutics operates in the highly specialized market of gene therapy, which is rapidly evolving and holds significant promise for addressing unmet medical needs.
SwanBio's business model revolves around research and development (R&D) of gene therapies, clinical trials, and eventual commercialization of successful treatments. Revenue generation is expected through partnerships, licensing agreements, and direct sales of approved therapies. The company is backed by knowledgeable investors and led by a team of experienced professionals with deep expertise in biopharma and healthcare sectors.
Key clients include healthcare providers, research institutions, and patients who are in dire need of innovative treatments for neurological disorders. SwanBio Therapeutics is headquartered in the biotech hubs of the greater Philadelphia and Boston areas, providing extraordinary career opportunities for professionals in the field.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lower Merion Township, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 62.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning SwanBio Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2023 | $10M | $280M | Syncona | ↗ |
| SERIES BOther financing | May 2022 | $56M | $224M | Syncona · Mass General Brigham Ventures | ↗ |
Growth signals
Latest recorded traffic for SwanBio Therapeutics is 1.1K monthly website visits, up 139.1% over the last three months. SwanBio Therapeutics's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Syncona
Mass General Brigham Ventures
Other known investors1 additional known investor
Harvard Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SwanBio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SwanBio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.